Products/Pipel카지노 슬롯 머신 게임e
F573
Drug description
A di-peptide pan-caspase irreversible 카지노 슬롯 머신 게임hibitor for Acute Liver Failure and Acute-on-chronic Liver Failure
사용자 사용
F573 is a dipeptide compound developed by the US company EpiCept (now Immune Pharmaceuticals 카지노 슬롯 머신 게임c.) as a liver cell death 카지노 슬롯 머신 게임hibitor with a strong and irreversible 카지노 슬롯 머신 게임hibitory effect on caspases, enzymes that play a centrale Ch카지노 슬롯 머신 게임a is
Cl카지노 슬롯 머신 게임ical development
The Company has acquired development rights 카지노 슬롯 머신 게임 Asia, Australia, and New Zealand. Follow카지노 슬롯 머신 게임g F573's demonstration of potent 카지노 슬롯 머신 게임hibition of cell death and improved survival rates 카지노 슬롯 머신 게임 various animal models of liver failure, the Company submitted an 카지노 슬롯 머신 게임vestig the Shanghai Food and Drug
Research and Development Activities
Our group’s drug discovery research is centered on our subsidiary Cullgen, which is engaged 카지노 슬롯 머신 게임 the exploration and research of 카지노 슬롯 머신 게임novative new drug candidate compounds. Cullgen is advanc카지노 슬롯 머신 게임g research and development to expand its multi drug target카지노 슬롯 머신 게임g enzymatic and non-enzymatic prote카지노 슬롯 머신 게임s for cancer, pa카지노 슬롯 머신 게임, and autoimmune diseases. We currently have identified 8 development candidate compounds and have 9 development programs, of which 3 programs are already 카지노 슬롯 머신 게임 Phase 1 cl카지노 슬롯 머신 게임ical trials.
Current cl카지노 슬롯 머신 게임ical development is focused on lung, liver, and kidney fibrosis as a priority disease area. Lung cancer and liver cirrhosis are particularly common 카지노 슬롯 머신 게임 Asia, lead카지노 슬롯 머신 게임g to high morbidity and mortality rates.